
Episode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv Banking
Between the Biotech Waves
00:00
Is There a Pain Point Now?
The probability or possibility of a turnaround in the first second quarter is dependent on investor interest, right? And their willingness to step back into the market. Are we at that pain point now? I would say we're there not just because of the passage of time and you've been sitting on cash for too long. There's some really positive things that have happened. Can these precision medicines, these gene therapies, these cell therapies be commercially successful? You know, are people still actually pretty jaded, still very cautious? Yes.
Transcript
Play full episode